Literature DB >> 8634997

Preoperative evaluation and staging of endometrial cancer.

J J Mikuta1.   

Abstract

Preoperative examination of a patient for whom a diagnosis of endometrial cancer has been made by office biopsy or dilatation and curettage includes careful history taking and physical examination, with emphasis on the pelvic examination, blood tests, and imaging evaluations of the pelvis, abdomen and chest, and other specific studies related to medical operability. The primary approach to endometrial cancer is surgery, which has been used for staging and treatment since the adoption of the Federation of Obstetrics and Gynecology system in 1988. Pilot studies and the Gynecologic Oncology Group have researched this system extensively and have emphasized the findings that could be defined only by pathologic study of the uterus, adnexa, retroperitoneal lymph nodes, and peritoneal cytologic findings. Preoperative endocervical evaluation is no longer necessary unless gross invasion of the cervix is suspected. However, initial histologic findings can identify patients at high risk, that is, those with high grade adenocarcinomas, clear cell carcinomas, adenosquamous carcinomas, and papillary serous adenocarcinomas. Intraoperative pathologic evaluation of the uterus by frozen section, which reveals depth of invasion into the myometrium and correlation with tumor grade, can identify patients for whom lymph node sampling should be performed.

Entities:  

Mesh:

Year:  1995        PMID: 8634997     DOI: 10.1002/1097-0142(19951115)76:10+<2041::aid-cncr2820761322>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Allelic loss at TP53 in metastatic human endometrial carcinomas.

Authors:  Wiktor Szewczuk; Danuta Skomra; Marek Cybulski; Dorota Przadka-Rabaniuk; Agata Filip; Maciej Jóźwik; Piotr Olcha; Albert Roessner; Andrzej Semczuk
Journal:  Clin Exp Metastasis       Date:  2009-06-30       Impact factor: 5.150

2.  p16INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas.

Authors:  Andrzej Semczuk; Carsten Boltze; Barbara Marzec; Anna Szczygielska; Albert Roessner; Regine Schneider-Stock
Journal:  J Cancer Res Clin Oncol       Date:  2003-08-14       Impact factor: 4.553

3.  P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome.

Authors:  Ryszard Jeczen; Danuta Skomra; Marek Cybulski; Regine Schneider-Stock; Wiktor Szewczuk; Albert Roessner; Tomasz Rechberger; Andrzej Semczuk
Journal:  Clin Exp Metastasis       Date:  2007-08-02       Impact factor: 4.510

4.  Common mitochondrial polymorphisms as risk factor for endometrial cancer.

Authors:  Anna M Czarnecka; Aleksandra Klemba; Andrzej Semczuk; Katarzyna Plak; Barbara Marzec; Tomasz Krawczyk; Barbara Kofler; Pawel Golik; Ewa Bartnik
Journal:  Int Arch Med       Date:  2009-10-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.